EMA consults on use of pharmacogenomics for evaluating authorised drugs
This article was originally published in SRA
The European Medicines Agency is seeking feedback on its plan to develop guidance on the use of pharmacogenomics in the pharmacovigilance evaluation of authorised medicines1,2.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.